Last checked at 5 Nov 2009 07:00
| For immediate release | 5 November 2009 |
ALLIANCE PHARMA PLC
("Alliance" or "the Company")
Trading Update
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, is pleased to report that trading continues to be very strong.
Sales in the nine months ended 30 September 2009 were £21.4m, up 44% from the £14.9m achieved in the same period in 2008, reflecting the positive sales trends reported at the time of the Company's interim results. Sales by Alliance of Buccastem® and Timodine®, the two brands acquired by the Company in August 2009, have been in line with management's expectations since their acquisition.
If the recent strong trading performance continues for the remainder of the year, the Board expects the Group's profit before tax for 2009 to significantly exceed its previous expectations.
The Company intends to provide a further trading update for the full year in January 2010.
For further information:
| Alliance Pharma plc | + 44 (0) 1249 466966 |
| John Dawson, Chief Executive | |
| Richard Wright, Finance Director | |
| www.alliancepharma.co.uk | |
| | |
| Buchanan Communications | + 44 (0) 20 7466 5000 |
| Mark Court / Stasa Filiplic / Jennie Spivey | |
| | |
| Numis Securities Limited | + 44 (0) 20 7260 1000 |
| Nominated Adviser: Michael Meade / Brent Nabbs | |
| Corporate Broking: David Poutney | |
Notes to editors
About Alliance Pharma
Alliance Pharma, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The company has a strong track record of acquiring the rights to established niche brands and owns, or licenses, the rights to 37 branded pharmaceutical products and continues to explore opportunities to expand the range.
Alliance Pharma's products are prescribed in the treatment of a wide range of conditions and include brands used in the treatment of dermatological conditions, in childbirth, in the prevention of heart disease, in Parkinson's disease, in nutrition and in nasal infections. Alliance Pharma's sales are mainly prescription driven. Its products are distributed to hospitals directly and to pharmaceutical wholesalers, which service both hospital and retail pharmacies with their prescription requirements.
Alliance Pharma joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.